CEO | President | Board member

Chief Financial Officer

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

United States Prostate Cancer Biomarkers Market Research Report 2025-2033: Rising Disease Prevalence, Advanced Diagnostics, and Regional Adoption in States Like California, Texas, New York, Florida

Oncology Companion Diagnostics Market Growth Is Fueled by The Rapid Adoption of Precision Medicine Till 2030

Myriad Genetics adds F8, FXN genest to Foresight Universal Plus Panel

Interim Chief of Staff, Finance

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all. The Chief of Staff to the CFO serves as a strategic partner and integrator within the Finance organization, ensuring effective execution of priorities and alignment across various functions.

Sign up with Google

Sign in with Google